Accelus Launches Ultra-Low Profile FlareHawk7™ Expandable Cage Implant & Innovative Instruments

Accelus, a privately held medical technology company focused on accelerating the adoption of minimally invasive surgery (MIS) as the standard of care in spine, today announced the launch of FlareHawk7, a multidirectionally expandable lumbar fusion device that is inserted at an ultra-low profile of 7mm to help minimize neural retraction before expanding in both the cranial-caudal and medial-lateral planes to provide sagittal and coronal correction, foraminal height restoration, and the stability to promote fusion.

The FlareHawk7 platform also features a suite of instruments designed to facilitate surgeons’ technique preferences. For endoscopic TLIF procedures, surgeons can leverage access with instruments to allow direct visualization of disc preparation and implant delivery. For MIS procedures, surgeons are provided access to the disc space through Kambin’s triangle while also preserving the patient’s normal anatomy. And in a “mini-open” procedure, the need for neural retraction can be minimized thanks to the smaller insertion footprint that is similar in profile to a No. 2 pencil.

“FlareHawk7 enables me to do fully endoscopic interbody fusion as outpatient surgery, with the best endplate prep and great clinical results,” said Jian Shen, M.D., PhD, a world-renowned leader in endoscopic spine surgery.

FlareHawk7 permits concurrent expansion in height and width to restore disc height without sacrificing stability. It enters the disc space with a compact 7mm x 7mm profile and then expands up to 11mm x 12mm—a 57% increase in width and 72% increase in height—with 0° and 6° lordosis options. This provides a larger surface contact area to distribute load with the goal of reducing subsidence in weak, osteoporotic bone. The implant’s open architecture design also allows significant graft delivery through the implant and into the surrounding disc space.

“FlareHawk7 is a game changer,” said Jason Huffman, M.D., a recognized leader in minimally invasive spinal fusion and Director of the Huffman Clinic in Napa, Calif. “It enables me to quickly and effectively perform a thorough discectomy and interbody fusion with a kick-ass, multiplanar-expandable, structured cage while utilizing a minimally invasive, percutaneous approach through Kambin’s triangle.”

Dr. Paul Houle, M.D., board-certified neurosurgeon with Cape Cod Healthcare Neurosurgery in Hyannis, Mass. agrees. “Historically, my surgical options were greatly limited when patients presented with scarring,” Dr. Houle said. “However, FlareHawk’s narrow insertion profile means I can treat these patients from a single position posteriorly – something not offered by other products currently on the market.”

The first-of-its-kind FlareHawk® family of implants utilizes a PEEK shell and internal shim, providing a small insertion profile to minimize neural retraction during insertion and then allowing expansion in height, width and lordosis, designed to reduce subsidence, restore foraminal height and re-establish sagittal balance. Peer-reviewed studies have suggested FlareHawk’s Adaptive Geometry to be a potential contributor to the implant’s positive fusion rates, as well as to the absence of observed subsidence1-4, a concern with monolithic cages that present a mismatch in the modulus of elasticity between the implant and the bone. To date, over 10,500 FlareHawk cages have been implanted in more than 9,000 patients.

“No other implant represents our philosophies of Adaptive Geometry and Access Without Compromise™ as well as FlareHawk7 with its ultra-low 7mm insertion profile expanding to 11mm, a full 2mm wider than the average 9mm TLIF implant. This allows for less neural retraction yet more footprint than current devices,” said Chris Walsh, CEO of Accelus. “We refuse to be dogmatic in our approach, as FlareHawk7 enables endoscopic, percutaneous, mini-open, and two-implant open PLIF procedures—all benefiting from Accelus’s Access without Compromise promise.”

SourceAccelus
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version